Aptinyx to Present at the 2019 BMO Prescription for Success Healthcare Conference
June 18, 2019 08:27 ET
|
Aptinyx Inc.
EVANSTON, Ill., June 18, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Positive Top-line Data from Phase 2 Study of NYX-2925 in Patients with Fibromyalgia, Demonstrating Significant Effects on Both Biomarkers and Patient-Reported Pain
June 10, 2019 07:23 ET
|
Aptinyx Inc.
NYX-2925 demonstrated statistically significant effects on a range of neuroimaging biomarkers and patient-reported outcomes, including pain scores Neuroimaging biomarkers correlated with...
Aptinyx Reports First Quarter 2019 Financial Results and Provides Corporate Update
May 14, 2019 06:27 ET
|
Aptinyx Inc.
Four Phase 2 studies expected to be ongoing by year end; multiple data read-outs anticipated in 2019 and 2020 Management to host conference call today at 8:00 a.m. ET EVANSTON, Ill., May 14, 2019 ...
Aptinyx to Report First Quarter 2019 Financial Results on Tuesday, May 14, 2019
May 06, 2019 07:27 ET
|
Aptinyx Inc.
EVANSTON, Ill., May 06, 2019 (GLOBE NEWSWIRE) -- Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...
Aptinyx Reports Positive Data from Phase 1 Study of Novel NMDA Receptor Modulator, NYX-458, in Healthy Volunteers
April 30, 2019 07:27 ET
|
Aptinyx Inc.
Favorable overall safety, tolerability, and pharmacokinetic profile—no serious adverse events reported across wide dose range Achieved ample CNS exposure consistent with exposure observed at...
Funcl Introduces Wireless Headphones That Deliver Big Sound and Popular Features at Affordable Prices
November 06, 2018 09:04 ET
|
Funcl
Funcl W1 and Funcl AI make wireless headphones accessible to consumers SAN FRANCISCO, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Funcl is poised to make wireless headphones more accessible to consumers –...
Aptinyx Presents Preclinical Data from Fast-Track Designated PTSD Program at Military Health System Research Symposium
August 21, 2018 06:35 ET
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Reports Second Quarter 2018 Financial and Business Results
August 14, 2018 06:27 ET
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...
Aptinyx Initiates Phase 1 Study of NYX-458
August 02, 2018 08:00 ET
|
Aptinyx Inc.
EVANSTON, Ill., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous...